Answers are grounded in this paper and cite their sources.
cancer screening strategies in low-resource settings: clinical benefits and cost effectiveness. JAMA. 2001;285:3107-3115. 25. Crum CP. The beginning of the end for cervical cancer? N Engl J Med. 2002; 347:1703-1705. 26. Skjeldstad FE, Koustsky L; for theMerck Phase III HPV Vaccine Steering Com-mittee (FUTURE II). Phase III trial of prophylactic quadrivalent HPV 6, 11, 16, 18 L1 virus-like particle (VLP) vaccine: prevention of cervical intraepithelial neoplasia (CIN) 2/3 including adeno- and squamous-cell carcinoma in situ (CIS). Presented
No takes yet. Share an insight, caveat, or question.
Stuart Pocock (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: